A prospective, randomised, double blind, placebo-controled, multi-centre trial to assess safety, efficacy, tolerability and immunogencity of influenza virus vaccine, trivalent types A & B, live cold-adapted, liquied formulation (CAIV-T), administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11-24 months
Download
Adobe PDF
(3.57 MB)